JAMA July 4, 2017, Vol 318, No. 1, Pages 7-102

July 4, 2017, Vol 318, No. 1, Pages 7-102

Financing and Distribution of Pharmaceuticals in the United States
Matan C. Dabora, MD, MBA; Namrata Turaga, MD, MBA; Kevin A. Schulman, MD
free access
JAMA. 2017;318(1):21-22. doi:10.1001/jama.2017.5607
This Viewpoint identifies stakeholders in the financing and distribution of pharmaceuticals in the United States and describes their flow from manufacturers through distributors, managers, and retailers to patients.

No Shortcuts on the Long Road to Evidence-Based Genomic Medicine
Muin J. Khoury, MD, PhD
JAMA. 2017;318(1):27-28. doi:10.1001/jama.2017.6315
This Viewpoint discusses the 2017 National Academies of Sciences, Engineering, and Medicine (NASEM) report on improving the system of evaluation of genetic testing so that implementation of genomic medicine in clinical settings can be evidence-based.
Rapid advances in genomics have led to a new era of precision medicine, resulting in a substantial increase in the number of genetic tests available for research and clinical practice. As of April 27, 2017, the Genetic Testing Registry,1 maintained and updated by the National Institutes of Health, contained information on 49 521 tests conducted at 492 laboratories for 10 733 disease conditions involving 16 223 genes. These tests cover a wide variety of diseases, rare and common, for different types of applications such as diagnosis, treatment, and prevention.